FDA Grants Bright Path AMT Designation as It Moves to Reshore America’s Medicines and Reduce Reliance on China
The designation covers Bright Path’s end-to-end U.S. production of two hospital medicines in chronic shortage, the first proof that essential medicines can be made in America, in most cases at prices that beat China and Indi
September 14, 2026